Results 51 to 60 of about 5,767,757 (296)
Anales de Pediatría, 2018 Resumen: Introducción: La hormona de crecimiento humana recombinante biosimilar (rhGH) fue el primer medicamento autorizado por la Agencia Europea del Medicamento (EMA), en el año 2006, por la vía de registro biosimilar.
Juan Pedro López-Siguero +4 more
doaj +1 more source
Growth Hormone Stimulation Testing: To Test or Not to Test? That Is One of the Questions
Frontiers in Endocrinology, 2022 The evaluation of children with short stature includes monitoring over a prolonged period to establish a growth pattern as well as the exclusion of chronic medical conditions that affect growth.
Mabel Yau, Robert Rapaport
doaj +1 more source
Phosphoinositides and inositol phosphates as molecular glues
FEBS Letters, EarlyView.Inositol phosphates (IPs) and phosphoinositides (PIPs) regulate diverse eukaryotic processes. Beyond recruiting signaling proteins or acting as structural cofactors, recent studies suggest they mediate protein–protein interactions as natural molecular glues.
Aleshia Seaton‐Terry +9 more
wiley +1 more source
Italian Journal of Pediatrics, 2019 Background The treatment with recombinant human growth hormone in patients affected by Mucopolysaccharidoses (MPS) is considered whenever a concurrent diagnosis of growth hormone deficiency is demonstrated. The short- and long-term effects of recombinant
A. Cattoni +5 more
doaj +1 more source
Hyperinsulinemic Hypoglycemia and Growth Hormone Deficiency Secondary to 20p11 Deletion
Case Reports in Endocrinology, 2023 Hypoglycemia is concerning for neurological complications in infants and children. Determining the cause of hypoglycemia is essential in providing appropriate treatment.
Erica Wee +5 more
doaj +1 more source
FEBS Letters, EarlyView.Inositol pyrophosphates are energy‐rich signaling molecules that perform critical functions in cells. Three different families of phosphatases hydrolyze the β phosphate of the inositol pyrophosphate molecules: two have narrow specificities and one is promiscuous.
Ronda J. Rolfes
wiley +1 more source
Treatment of growth hormone deficiency in adults
, 2009 BACKGROUND: The Growth Hormone Research Society held a Consensus Workshop in Sydney, Australia, in March 2007 to review advances in the management of growth hormone (GH) deficiency in adults and to update consensus recommendations.
Johannsson, Gudmundur,
core +1 more source
Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential
FEBS Letters, EarlyView.Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta +3 more
wiley +1 more source
Growth hormone deficiency and cerebral palsy
Therapeutics and Clinical Risk Management, 2010 Jesús Devesa1,2, Nerea Casteleiro2, Cristina Rodicio2, Natalia López2, Pedro Reimunde1,21Department of Physiology, School of Medicine of Santiago de Compostela, Spain; 2Medical Center Proyecto Foltra, 15886 Teo, SpainAbstract ...
Jesús Devesa +3 more
doaj
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source